FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381251431> ?p ?o ?g. }

• W4381251431 endingPage "695" @default.
• W4381251431 startingPage "685" @default.
• W4381251431 abstract "Phenylketonuria (PKU) is an inborn error of metabolism caused by deficient activity of phenylalanine hydroxylase. In Brazil, the National Neonatal Screening Program enables early treatment of patients with PKU, which prevents them from developing severe neurological damage and mental disabilities. However, between 20 and 30% of early-treated patients with PKU present focal cognitive deficits, including deficits in working memory, processing speed, and psychiatric symptoms such as anxiety, depression, and attention deficit hyperactivity disorder (ADHD). Therefore, age-specific neuropsychiatric and cognitive tests are important components of PKU patient care. To date, there are no officially approved guidelines or recommendations of tools in Portuguese validated for use in Brazil that could be applied to assess these parameters in patients with PKU.To recommend tools validated for use in Brazil that can be used in daily clinical practice to assess quality of life and neuropsychological outcomes in patients with PKU.Six Brazilian experts discussed about eligible tools based on their clinical experience, the feasibility of their use in clinical routines, and their availability in public health services. Before the meeting, an independent review of the literature was conducted to identify the currently validated tools in Brazil, using the MEDLINE and SciELO databases.The experts recommended nine tools to assess quality of life (Peds-QL, SF-36 or WHOQOL-bref), executive function (BRIEF or Bayley-III), IQ (SONR 2½-7[a] or WASI) and ADHD (MTA-SNAP-IV and ASRS).These instruments may be easily incorporated into clinical practice and improve the quality of multidisciplinary care of patients with PKU.A fenilcetonúria (PKU) é um erro inato do metabolismo causado pela atividade deficiente da fenilalanina hidroxilase. No Brasil, o Programa Nacional de Triagem Neonatal permite o tratamento precoce de pacientes com PKU, o que os impede de desenvolver danos neurológicos e deficiências intelectuais graves. No entanto, já foi descrito que de 20 a 30% dos pacientes tratados precocemente com PKU apresentam déficits cognitivos focais, incluindo déficits na memória de trabalho, velocidade de processamento e sintomas psiquiátricos como ansiedade, depressão e Transtorno de Déficit de Atenção e Hiperatividade (TDAH). Neste sentido, testes neuropsiquiátricos e cognitivos são componentes importantes no cuidado destes pacientes. Atualmente, não existe um compêndio científico ou recomendações de ferramentas validadas em português para avaliar a saúde mental em pacientes brasileiros com PKU.Recomendar ferramentas validadas localmente para avaliar a qualidade de vida e aspectos neuropsicológicos de pacientes com PKU. MéTODOS: Seis especialistas brasileiros discutiram as ferramentas mais apropriadas com base em suas experiências clínicas, a viabilidade de realizar as avaliações na rotina clínica, e o acesso às ferramentas na saúde pública. Antes da reunião, foi realizada uma revisão independente da literatura para identificar as ferramentas validadas no Brasil, utilizando as bases de dados MEDLINE e Scielo.Os especialistas recomendaram nove ferramentas para avaliar a qualidade de vida (Peds-QL, SF-36 ou WHOQOL-bref), função executiva (BRIEF ou Bayley-III), QI (SONR 2½-7[a] ou WASI) e TDAH (MTA-SNAP-IV e ASRS). CONCLUSãO: Estes instrumentos podem ser facilmente incorporados na prática clínica e melhorar a qualidade dos cuidados multidisciplinares dos pacientes com PKU." @default.
• W4381251431 created "2023-06-20" @default.
• W4381251431 creator A5020113336 @default.
• W4381251431 creator A5021923333 @default.
• W4381251431 creator A5021968370 @default.
• W4381251431 creator A5062421270 @default.
• W4381251431 creator A5066187182 @default.
• W4381251431 creator A5078435186 @default.
• W4381251431 date "2023-06-19" @default.
• W4381251431 modified "2023-10-01" @default.
• W4381251431 title "Neuropsychological and quality of life outcomes in PKU patients: expert recommendations of assessment tools in Brazil" @default.
• W4381251431 cites W1548203477 @default.
• W4381251431 cites W1562820984 @default.
• W4381251431 cites W1580806590 @default.
• W4381251431 cites W1842911909 @default.
• W4381251431 cites W1845447069 @default.
• W4381251431 cites W1990591430 @default.
• W4381251431 cites W1994323473 @default.
• W4381251431 cites W2001072757 @default.
• W4381251431 cites W2006682072 @default.
• W4381251431 cites W2013707218 @default.
• W4381251431 cites W2014347628 @default.
• W4381251431 cites W2017306890 @default.
• W4381251431 cites W2020993265 @default.
• W4381251431 cites W2021623845 @default.
• W4381251431 cites W2024268322 @default.
• W4381251431 cites W2027096288 @default.
• W4381251431 cites W2028298694 @default.
• W4381251431 cites W2034797974 @default.
• W4381251431 cites W2037377025 @default.
• W4381251431 cites W2043358844 @default.
• W4381251431 cites W2056064838 @default.
• W4381251431 cites W2060765936 @default.
• W4381251431 cites W2062141746 @default.
• W4381251431 cites W2070682452 @default.
• W4381251431 cites W2071199156 @default.
• W4381251431 cites W2076238820 @default.
• W4381251431 cites W2077675998 @default.
• W4381251431 cites W2078176863 @default.
• W4381251431 cites W2082822387 @default.
• W4381251431 cites W2086428720 @default.
• W4381251431 cites W2101972169 @default.
• W4381251431 cites W2102526697 @default.
• W4381251431 cites W2110524682 @default.
• W4381251431 cites W2119620905 @default.
• W4381251431 cites W2132423376 @default.
• W4381251431 cites W2135605417 @default.
• W4381251431 cites W2142468239 @default.
• W4381251431 cites W2155719587 @default.
• W4381251431 cites W2168448906 @default.
• W4381251431 cites W2189462636 @default.
• W4381251431 cites W2285706350 @default.
• W4381251431 cites W2323149989 @default.
• W4381251431 cites W2345658596 @default.
• W4381251431 cites W2429180991 @default.
• W4381251431 cites W2547207239 @default.
• W4381251431 cites W2570496805 @default.
• W4381251431 cites W2572123485 @default.
• W4381251431 cites W2593927658 @default.
• W4381251431 cites W2601570036 @default.
• W4381251431 cites W2774793874 @default.
• W4381251431 cites W2793449864 @default.
• W4381251431 cites W2795291721 @default.
• W4381251431 cites W2879780745 @default.
• W4381251431 cites W2919874265 @default.
• W4381251431 cites W2933238298 @default.
• W4381251431 cites W2942355434 @default.
• W4381251431 cites W2947923636 @default.
• W4381251431 cites W2957007442 @default.
• W4381251431 cites W2980592459 @default.
• W4381251431 cites W2993956196 @default.
• W4381251431 cites W3012849739 @default.
• W4381251431 cites W3042012431 @default.
• W4381251431 cites W3042266870 @default.
• W4381251431 cites W3095150447 @default.
• W4381251431 cites W3215668516 @default.
• W4381251431 cites W4200187222 @default.
• W4381251431 cites W4249791806 @default.
• W4381251431 cites W4292806894 @default.
• W4381251431 cites W634200373 @default.
• W4381251431 doi "https://doi.org/10.1055/s-0043-1768677" @default.
• W4381251431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37336507" @default.
• W4381251431 hasPublicationYear "2023" @default.
• W4381251431 type Work @default.
• W4381251431 citedByCount "0" @default.
• W4381251431 crossrefType "journal-article" @default.
• W4381251431 hasAuthorship W4381251431A5020113336 @default.
• W4381251431 hasAuthorship W4381251431A5021923333 @default.
• W4381251431 hasAuthorship W4381251431A5021968370 @default.
• W4381251431 hasAuthorship W4381251431A5062421270 @default.
• W4381251431 hasAuthorship W4381251431A5066187182 @default.
• W4381251431 hasAuthorship W4381251431A5078435186 @default.
• W4381251431 hasBestOaLocation W43812514311 @default.
• W4381251431 hasConcept C118552586 @default.
• W4381251431 hasConcept C14216870 @default.
• W4381251431 hasConcept C159110408 @default.
• W4381251431 hasConcept C169900460 @default.
• W4381251431 hasConcept C17744445 @default.

• next